Home › Compare › KAMRF vs ABBV
KAMRF yields 1818.18% · ABBV yields 3.06%● Live data
📍 KAMRF pulled ahead of the other in Year 1
Combined, KAMRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KAMRF + ABBV for your $10,000?
Kalamazoo Resources Limited explores for and develops gold and base metal properties in Australia. The company also explores for nickel and cobalt deposits. It holds interests in the Castlemaine project that consists of three exploration licenses covering an area of approximately 310 square kilometers; the South Muckleford project that comprises an area of approximately 161 square kilometers; the Tarnagulla project; and the Myrtle project located in Victoria. The company also holds interests in the Pilbara projects, including the Ashburton project comprising 4 mining leases and 3 exploration licenses covering an area of approximately 217 square kilometers; the DOM's Hill project that covers an area of approximately 125 square kilometers; the Marble Bar project covering an area of approximately 125 square kilometers; the Pear Creek lithium project covering an area of approximately 147 square kilometers; and the Sisters project covering an area of approximately 239 square kilometers situated in Western Australia. Kalamazoo Resources Limited was incorporated in 2011 and is headquartered in West Perth, Australia.
Full KAMRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.